Get the Stockscreener App
0.2653
3.11%
-0.0078
Adaptimmune Therapeutics Plc Adr stock is traded at $0.2653, with a volume of 413.22K.
It is down -3.11% in the last 24 hours and down -4.37% over the past month.
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
See More
Previous Close:
$0.2731
Open:
$0.282
24h Volume:
413.22K
Relative Volume:
0.23
Market Cap:
$420.96M
Revenue:
$175.04M
Net Income/Loss:
$-44.52M
P/E Ratio:
-1.4739
EPS:
-0.18
Net Cash Flow:
$-56.05M
1W Performance:
-5.53%
1M Performance:
-4.37%
6M Performance:
-63.29%
1Y Performance:
-73.80%
1-Day Range:
$0.2554
$0.282
1-Week Range:
$0.2554
$0.2996
52-Week Range:
$0.1951
$1.48
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Name
Adaptimmune Therapeutics Plc Adr
Sector
Industry
Phone
44 1235 430000
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Compare ADAP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.2647 | 72.73M | 175.04M | -44.52M | -56.05M | -0.18 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.32 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.47 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.98 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Outperform |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-09-22 | Upgrade | Mizuho | Neutral → Buy |
| May-28-21 | Initiated | Barclays | Underweight |
| Apr-22-20 | Initiated | Mizuho | Neutral |
| Aug-02-19 | Downgrade | Guggenheim | Buy → Neutral |
| May-31-19 | Initiated | ROTH Capital | Buy |
| May-30-19 | Resumed | Citigroup | Buy |
| May-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-17-17 | Initiated | Wells Fargo | Market Perform |
| Oct-24-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Sep-30-16 | Initiated | Raymond James | Outperform |
| Feb-25-16 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | BofA/Merrill | Neutral |
| Jun-01-15 | Initiated | Guggenheim | Buy |
| Jun-01-15 | Initiated | Leerink Partners | Outperform |
View All
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.26, Down by -5.05 - DWinneX
Bausch + Lomb Corp (NYSE:BLCO)’s 12-Month Price Target Is Now Set At 23. - Marketing Sentinel
B. Riley Financial Inc (NASDAQ:RILY) Shares Dropped -2.22% In A Week. Can It Continue Rising? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Could Really Rise To 4 In 12 Months, According To Analysts. - Marketing Sentinel
Is Live Oak Bancshares Inc (NYSE:LOB) A Better Buy Than Others After A -32.27% Fall In This Year? - Marketing Sentinel
Eventbrite Inc (NYSE:EB) Declines -81.18% In 2025; Are Investors Attracted By Its $2.10 Price? - Marketing Sentinel
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
TransCode Therapeutics Inc: Weathering Stock Market Storms with 8.59M Market Cap - investchronicle.com
Charting the Course: Tempest Therapeutics Inc’s TPST Stock Prospects - investchronicle.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics Plc ADR (ADAP)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater
SM Energy Co (SM): A Technical Analysis - The News Heater
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lunger John | Chief Patient Supply Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
| Bertrand William C JR | Chief Operating Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
| Rawcliffe Adrian | Chief Executive Officer |
Jan 17 '25 |
Sale |
0.58 |
30,601 |
17,773 |
44,327 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):